<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902025000100052</article-id>
<article-id pub-id-type="doi">10.29262/ram.v72i1.1433</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Reacciones adversas por anticuerpos monoclonales en el tratamiento de enfermedades alérgicas. Posicionamiento de Grupo: Comité de Alergia a Medicamentos del Colegio Mexicano de Inmunología Clínica y Alergia (CMICA 2024-2025)]]></article-title>
<article-title xml:lang="en"><![CDATA[Adverse reactions due to monoclonal antibodies in the treatment of allergic diseases. Group Positioning: Comité de Alergia a Medicamentos del Colegio Mexicano de Inmunología Clínica y Alergia (CMICA 2024-2025)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villarreal González]]></surname>
<given-names><![CDATA[Rosalaura Virginia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Perea Valle]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fraga Olvera]]></surname>
<given-names><![CDATA[Alira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ávila Lara]]></surname>
<given-names><![CDATA[Anabel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Delgado Bañuelos]]></surname>
<given-names><![CDATA[Angélica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Correa Serrano]]></surname>
<given-names><![CDATA[Carlos Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Rosas]]></surname>
<given-names><![CDATA[Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alonso Bello]]></surname>
<given-names><![CDATA[César Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rico Solís]]></surname>
<given-names><![CDATA[Germán Agustín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ochoa García]]></surname>
<given-names><![CDATA[Itzel Vianey]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez Heredia]]></surname>
<given-names><![CDATA[Jennifer]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Juárez]]></surname>
<given-names><![CDATA[Kitzia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreno González]]></surname>
<given-names><![CDATA[Maciel Monserrat]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortega Cisneros]]></surname>
<given-names><![CDATA[Margarita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Cruz]]></surname>
<given-names><![CDATA[Maria de la Luz Hortensia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arias Martínez]]></surname>
<given-names><![CDATA[Maria Isabel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Servín Suárez]]></surname>
<given-names><![CDATA[Nayell]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cortés Grimaldo]]></surname>
<given-names><![CDATA[Rosa María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz López]]></surname>
<given-names><![CDATA[Silvia Paulina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zecua Nájera]]></surname>
<given-names><![CDATA[Yahvén]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cadenas García]]></surname>
<given-names><![CDATA[Diana Estefanía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Autónoma de Nuevo León  ]]></institution>
<addr-line><![CDATA[Nuevo León ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Regional &#8220;Dr. Valentín Gómez Farías&#8221;  ]]></institution>
<addr-line><![CDATA[Jalisco ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,México  ]]></institution>
<addr-line><![CDATA[México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Amerimed Playa del Carmen  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Hospital ISSSTE Tláhuac  ]]></institution>
<addr-line><![CDATA[México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Hospital General Regional No. 58  ]]></institution>
<addr-line><![CDATA[Guanajuato ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Hospital General de Ensenada  ]]></institution>
<addr-line><![CDATA[Baja Califormia ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Hospital Juárez De México  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Hospitales Puerta de Hierro Colima  ]]></institution>
<addr-line><![CDATA[Colima ]]></addr-line>
<country>México</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Instituto Mexicano del Seguro Social  ]]></institution>
<addr-line><![CDATA[Jalisco ]]></addr-line>
<country>México</country>
</aff>
<aff id="A11">
<institution><![CDATA[,Instituto Mexicano del Seguro Social  ]]></institution>
<addr-line><![CDATA[Guanajuato ]]></addr-line>
<country>México</country>
</aff>
<aff id="A12">
<institution><![CDATA[,Hospital General de Zona No. 8  ]]></institution>
<addr-line><![CDATA[Veracruz ]]></addr-line>
<country>México</country>
</aff>
<aff id="A13">
<institution><![CDATA[,Hospital General de Zona 36 IMSS  ]]></institution>
<addr-line><![CDATA[Veracruz ]]></addr-line>
<country>México</country>
</aff>
<aff id="A14">
<institution><![CDATA[,Instituto Nacional de Enfermedades Respiratorias  ]]></institution>
<addr-line><![CDATA[México ]]></addr-line>
<country>México</country>
</aff>
<aff id="A15">
<institution><![CDATA[,Hospital General Regional 1  ]]></institution>
<addr-line><![CDATA[Querétaro ]]></addr-line>
<country>México</country>
</aff>
<aff id="A16">
<institution><![CDATA[,Núcleo Médico Galenos  ]]></institution>
<addr-line><![CDATA[Michoacán ]]></addr-line>
<country>México</country>
</aff>
<aff id="A17">
<institution><![CDATA[,Centro Médico Nacional de Occidente  ]]></institution>
<addr-line><![CDATA[Jalisco ]]></addr-line>
<country>México</country>
</aff>
<aff id="A18">
<institution><![CDATA[,Hospital Ángeles León  ]]></institution>
<addr-line><![CDATA[Guanajuato ]]></addr-line>
<country>México</country>
</aff>
<aff id="A19">
<institution><![CDATA[,Centro Médico San Carlos  ]]></institution>
<addr-line><![CDATA[Tlaxcala ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<volume>72</volume>
<numero>1</numero>
<fpage>52</fpage>
<lpage>71</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902025000100052&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902025000100052&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902025000100052&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: Los anticuerpos monoclonales representan una opción de tratamiento en pacientes con enfermedades alérgicas, autoinmunes, oncológicas, entre otras. Su función consiste en inhibir las interacciones entre moléculas efectoras y sus receptores específicos. Sin embargo, el aumento de su prescripción ha provocado un incremento de las reacciones adversas a medicamentos. Este tipo de reacciones son respuestas dañinas e inesperadas a tratamientos terapéuticos. Se dividen en tipo A, relacionadas con la acción del medicamento y sus interacciones, y tipo B, asociadas con reacciones de hipersensibilidad.  Objetivos: Se llevó a cabo una revisión bibliográfica de la prescripción de anticuerpos monoclonales en el tratamiento de enfermedades alérgicas, abordando la farmacocinética, farmacodinámica, posología, contraindicaciones y reacciones adversas.  Metodología: La búsqueda de información se realizó en las principales bases de datos médicas, acerca de los anticuerpos monoclonales para el tratamiento de enfermedades alérgicas. La búsqueda se limitó a artículos originales, en idioma inglés y español, publicados entre 2014 y 2024. Se describe la actualización de la información relacionada con anticuerpos monoclonales para enfermedades alérgicas, incluyendo su mecanismo de acción, nombre comercial, indicaciones, posología, contraindicaciones y reacciones adversas.  Conclusión: La recopilación de datos acerca de medicamentos biológicos es decisiva para la comprensión integral y actualizada de su prescripción clínica. Conocer las reacciones adversas mejora el entendimiento del diagnóstico y la calidad de la atención médica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Monoclonal antibodies are a therapeutic option for allergy, autoimmune, oncological diseases, among others, and work by inhibiting interactions between effector molecules and their specific receptors. However, the increasing use of these drugs has led to an increase in adverse drug reactions (ADRs). ADRs are defined as unexpected responses to therapeutic treatments. They are divided into type A, derived from the pharmacokinetics of the treatment or as a host immune response type B.  Objectives: Review of the use of monoclonal antibodies in the treatment of allergic diseases, addressing key aspects such as pharmacokinetics, pharmacodynamics, posology, contraindications and adverse reactions.  Methodology: A search of major medical databases on monoclonal antibodies for the treatment of allergic diseases was conducted. It was limited to original articles in English and Spanish, published between 2014 and 2024.  Results: Monoclonal antibodies for allergic diseases are described, including their mechanism of action, trade name, indications, posology, contraindications and adverse reactions.  Conclusion: The collection of data on biological drugs is crucial for a comprehensive and up-to-date understanding of their clinical use. Understanding adverse reactions improves diagnosis and the quality of medical care.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Anticuerpos monoclonales]]></kwd>
<kwd lng="es"><![CDATA[Reacción adversa a medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Reacciones de hipersensibilidad]]></kwd>
<kwd lng="es"><![CDATA[Farmacocinética]]></kwd>
<kwd lng="es"><![CDATA[Farmacodinámica]]></kwd>
<kwd lng="es"><![CDATA[Posología]]></kwd>
<kwd lng="es"><![CDATA[Contraindicaciones]]></kwd>
<kwd lng="es"><![CDATA[Reacciones adversas]]></kwd>
<kwd lng="en"><![CDATA[Monoclonal antibodies]]></kwd>
<kwd lng="en"><![CDATA[Adverse reactions to drugs]]></kwd>
<kwd lng="en"><![CDATA[Hypersensitivity reactions]]></kwd>
<kwd lng="en"><![CDATA[Pharmacokinetics]]></kwd>
<kwd lng="en"><![CDATA[Pharmacodynamics]]></kwd>
<kwd lng="en"><![CDATA[Posology]]></kwd>
<kwd lng="en"><![CDATA[Contraindications]]></kwd>
<kwd lng="en"><![CDATA[Adverse reactions]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>WHO Expert Committee on Biological Standardization</collab>
<article-title xml:lang=""><![CDATA[World Health Organ Tech Rep Ser]]></article-title>
<source><![CDATA[World Health Organ Tech Rep Ser]]></source>
<year>2014</year>
<numero>987</numero>
<issue>987</issue>
<page-range>1-266</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Saretta]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bianchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypersensitivity Reactions to Monoclonal Antibodies in Children]]></article-title>
<source><![CDATA[Medicina (Buenos Aires)]]></source>
<year>2020</year>
<volume>56</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>232</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozdemir]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monoclonal Antibodies in Allergy: Updated Applications and Promising Trials]]></article-title>
<source><![CDATA[Recent Pat Inflamm Allergy Drug Discov]]></source>
<year>2015</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>54-65</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zazzara]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vetrano]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Carfi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Onder]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug reactions in older adults: a narrative review of the literature]]></article-title>
<source><![CDATA[Eur Geriatr Med]]></source>
<year>2021</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>463-73</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pichler]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune pathomechanism and classification of drug hypersensitivity]]></article-title>
<source><![CDATA[Allergy Eur J Allergy Clin Immunol]]></source>
<year>2019</year>
<volume>74</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1457-71</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corominas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gastaminza]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lobera]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypersensitivity reactions to biological drugs]]></article-title>
<source><![CDATA[J Investig Allergol Clin Immunol]]></source>
<year>2014</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>212-25</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isabwe]]></surname>
<given-names><![CDATA[GAC]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia Neuer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de las Vecillas Sanchez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[D-M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2018</year>
<volume>142</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>159-170.e2</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>Food and Drug Administration</collab>
<article-title xml:lang=""><![CDATA[XOLAIR® (omalizumab) injection for subcutaneous use initial U.S. Approval 2003]]></article-title>
<source><![CDATA[XOLAIR® (omalizumab) injection for subcutaneous use initial U.S.]]></source>
<year>2003</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Purizaca-Bazán]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega-Martell]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bloqueo de inmunoglobulina E en el asma grave]]></article-title>
<source><![CDATA[Rev Alerg México]]></source>
<year>2020</year>
<volume>67</volume>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kavati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhdanava]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2019</year>
<volume>41</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1956-71</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casale]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Luskin]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Busse]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2019</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>156-164.e1</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canonica]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Rottoli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bucca]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study]]></article-title>
<source><![CDATA[World Allergy Organ J]]></source>
<year>2018</year>
<volume>11</volume>
<page-range>33</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhutani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Hébert]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de Takacsy]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Fehrenbach]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2017</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>e0183869</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Damask]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Holweg]]></surname>
<given-names><![CDATA[CTJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yoo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis]]></article-title>
<source><![CDATA[Am J Rhinol Allergy]]></source>
<year>2022</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>135-41</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seetasith]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Holden]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hetherington]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world outcomes in patients with chronic spontaneous urticaria receiving omalizumab: insights from a clinical practice survey]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2024</year>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Togias]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sicherer]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab for the Treatment of Multiple Food Allergies]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2024</year>
<volume>390</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>889-99</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chebani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lombart]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chaby]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2024</year>
<volume>190</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>258-65</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferri]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bellosta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Baldessin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Boccia]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics interactions of monoclonal antibodies]]></article-title>
<source><![CDATA[Pharmacol Res]]></source>
<year>2016</year>
<volume>111</volume>
<page-range>592-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[C]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Omalizumab]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dantzer]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update on omalizumab in allergen immunotherapy]]></article-title>
<source><![CDATA[Curr Opin Allergy Clin Immunol]]></source>
<year>2021</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>559-68</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Namazy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cabana]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Scheuerle]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2015</year>
<volume>135</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>407-12</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Namazy]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Blais]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2020</year>
<volume>145</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>528-536.e1</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monoclonal Antibodies During Breastfeeding]]></article-title>
<source><![CDATA[Breastfeed Med]]></source>
<year>2021</year>
<volume>16</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>591-3</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yakuwa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sandalji]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab concentrations in pregnancy and lactation: A case study]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2020</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3603-4</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Platts-Mills]]></surname>
<given-names><![CDATA[TAE]]></given-names>
</name>
<name>
<surname><![CDATA[Finegold]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2007</year>
<volume>120</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1373-7</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[MacRae]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Karsh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Santucci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience]]></article-title>
<source><![CDATA[Ann Allergy, Asthma Immunol]]></source>
<year>2015</year>
<volume>115</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bagnasco]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Canevari]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Del Giacco]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps]]></article-title>
<source><![CDATA[World Allergy Organ J]]></source>
<year>2022</year>
<volume>15</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>100721</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harb]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chatila]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of Dupliumab]]></article-title>
<source><![CDATA[Clin Exp Allergy]]></source>
<year>2020</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-14</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matsunaga]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Katoh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fujieda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Izuhara]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dupliumab: Basic aspects and applications to allergic diseases]]></article-title>
<source><![CDATA[Allergol Int]]></source>
<year>2020</year>
<volume>69</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>187-96</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="">
<collab>Food and Drug Administration</collab>
<source><![CDATA[DUPIXENT * (dupliumab) injection for subcutaneous use Initial]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sitek]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Pongdee]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risks and safety of biologics: A practical guide for allergists]]></article-title>
<source><![CDATA[World Allergy Organ J]]></source>
<year>2023</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>100737</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gade]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dupliumab]]></article-title>
<source><![CDATA[StatPearls]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khamisy-Farah]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Damiani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kong]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J-H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety profile of Dupllumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase&#8482;)]]></article-title>
<source><![CDATA[Eur Rev Med Pharmacol Sci]]></source>
<year>2021</year>
<volume>25</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>5448-51</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosma]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Gerbens]]></surname>
<given-names><![CDATA[LAA]]></given-names>
</name>
<name>
<surname><![CDATA[Middelkamp-Hup]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Spuls]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paternal and maternal use of duplumab in patients with atopic dermatitis: a case series]]></article-title>
<source><![CDATA[Clin Exp Dermatol]]></source>
<year>2021</year>
<volume>46</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1089-92</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adam]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Gooderham]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Beecker]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expert consensus on the systemic treatment of atopic dermatitis in special populations]]></article-title>
<source><![CDATA[J Eur Acad Dermatology Venereol]]></source>
<year>2023</year>
<volume>37</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1135-48</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wechsler]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Maspero]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term safety and efficacy of duplumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study]]></article-title>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2022</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-25</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albader]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Alharbi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Alenez!]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Alsai?]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dupllumab side effect in a patient with atopic dermatitis: a case report study]]></article-title>
<source><![CDATA[Biol Targets Ther]]></source>
<year>2019</year>
<volume>13</volume>
<page-range>79-82</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Partida-Gaytan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Torre-Bouscoulet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Macias]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Raimondi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nepolizumab para el tratamiento de asma grave eosinofílica]]></article-title>
<source><![CDATA[Rev Alerg Méx]]></source>
<year>2021</year>
<volume>67</volume>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="">
<collab>Food and Drug Administration</collab>
<source><![CDATA[NUCALA (Mepolizumab): Highlights of prescribing information]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pavord]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Korn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Howarth]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>380</volume>
<numero>9842</numero>
<issue>9842</issue>
<page-range>651-9</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Kornmann]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2022</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2100396</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Bachert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fokkens]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2021</year>
<volume>9</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1141-53</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steinfeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bradford]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of clinical benefit from treatment with nepolizumab for patients with eosinophilic granulomatosis with polyangritis]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2019</year>
<volume>143</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2170-7</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roufosse]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[J-E]]></given-names>
</name>
<name>
<surname><![CDATA[Rothenberg]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of nepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2020</year>
<volume>146</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1397-405</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ullmann]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Peri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Florio]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe Pediatric Asthma Therapy: Nepolizumab]]></article-title>
<source><![CDATA[Front Pediatr]]></source>
<year>2022</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition]]></article-title>
<source><![CDATA[Infect Dis Clin North Am]]></source>
<year>2020</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>211-34</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dighiri]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Aluugbayhir]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Albesisi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Safety of Nepolizumab in the Management of Severe Eosinophilic Asthma: A Systematic Review]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Middleton]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Gade]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilera]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2020</year>
<volume>55</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1901208</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vittorakis]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Giannakopoulou]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Samitas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zervas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful and safe treatment of severe steroid depended eosinophilic asthma with nepolizumab in a woman during pregnancy]]></article-title>
<source><![CDATA[Respir Med Case Reports]]></source>
<year>2023</year>
<volume>41</volume>
<page-range>101785</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozden]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pinar Deniz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[May nepolizumab used in asthma correct subfertility?]]></article-title>
<source><![CDATA[Ann Med]]></source>
<year>2021</year>
<volume>53</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>456-8</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domingo Ribas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Carrillo Díaz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco Aparicio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real World Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2021</year>
<volume>81</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1763-74</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giossi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schroeder]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Scaglione]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exploring the risk of infection events in patients with asthma receiving anti-IL-5 monoclonal antibodies: A rapid systematic review and a meta-analysis]]></article-title>
<source><![CDATA[Heliyon]]></source>
<year>2024</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e23725</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[S-C]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments]]></article-title>
<source><![CDATA[BMC Pulm Med]]></source>
<year>2024</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>70</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<collab>Committee for Propietary Medical Products EPAR</collab>
<article-title xml:lang=""><![CDATA[Fasenra® ficha tecnica del medicamento]]></article-title>
<source><![CDATA[The European Agency for the evaluation of medicinal products (EMEA)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laviolette]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gossage]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Gauvreau]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of benzalizumab on airway eosinophils in asthmatic patients with sputum eosinophilia]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2013</year>
<volume>132</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1086-1096.e5</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bachert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Desrosiers]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of benzalizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2022</year>
<volume>149</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1309-1317.e12</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nanzer]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Maynard-Paquette]]></surname>
<given-names><![CDATA[A-C]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangitis]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2024</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>724-32</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wedner]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fujisawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Guilbert]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (&lt;scp&gt;TATE&lt;/scp&gt; study)]]></article-title>
<source><![CDATA[Pediatr Allergy Immunol]]></source>
<year>2024</year>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Bleecker]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benralizumab, an anti-interleukin 5 receptor monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study]]></article-title>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2014</year>
<volume>2</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>879-90</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Markham]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benralizumab: First Global Approval]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2018</year>
<volume>78</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>505-11</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naftel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Eames]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kerley]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benralizumab treatment of severe asthma in pregnancy: A case series]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2023</year>
<volume>11</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2919-21</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kuvelkar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Murgolo]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5]]></article-title>
<source><![CDATA[Int Immunol]]></source>
<year>1999</year>
<volume>11</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1935-44</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="">
<source><![CDATA[Ficha Técnica Reslizumab]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[About severe eosinophilic asthma]]></article-title>
<source><![CDATA[CINQAIR]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="">
<collab>Teva Pharmaceuticals</collab>
<source><![CDATA[Reslizumab (Cinqaero): summary of product characteristics]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="">
<collab>Respiratory T</collab>
<article-title xml:lang=""><![CDATA[Cinqair (reslizumab) injection, for intravenous use: US prescribing information]]></article-title>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deeks]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Brusselle]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reslizumab in Eosinophilic Asthma: A Review]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2017</year>
<volume>77</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>777-84</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bjermer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2017</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1572-1581.e3</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[European public assessment report (EPAR): Cinqaero (reslizumab)]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="">
<source><![CDATA[Highlights of prescribing information]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfaller]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jose Yepes-Nunez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Agache]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biologicals in atopic disease in pregnancy: An EAACI position paper]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2021</year>
<volume>76</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-89</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baubek]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pagani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez-Cuesta]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypersensitivity reactions to biologicals: An EAACI position paper]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2022</year>
<volume>77</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-54</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuruvilla]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Vanijchanoenkarn]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shih]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[FE-H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and risk factors for asthma]]></article-title>
<source><![CDATA[Respir Med]]></source>
<year>2019</year>
<volume>149</volume>
<page-range>16-22</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pepper]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Hanania]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Casale]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2021</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1081-8</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Guan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anaphylactic risk related to omalizumab, bemalizumab, reslizumab, mepolizumab, and dupilumab]]></article-title>
<source><![CDATA[Clin Transl Allergy]]></source>
<year>2021</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pichler]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse side-effects to biological agents]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2006</year>
<volume>61</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>912-20</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hausmann]]></surname>
<given-names><![CDATA[OV]]></given-names>
</name>
<name>
<surname><![CDATA[Seitz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Villiger]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Pichler]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Complex Clinical Picture of Side Effects to Biologicals]]></article-title>
<source><![CDATA[Med Clin North Am]]></source>
<year>2010</year>
<volume>94</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>791-804</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Franzblau]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases]]></article-title>
<source><![CDATA[Curr Allergy Asthma Rep]]></source>
<year>2022</year>
<volume>22</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>195-207</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larkin]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapy Approved for All Types of Severe Asthma]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2022</year>
<volume>327</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>805</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menzies-Gow]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ponnarambil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Downie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bowen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma]]></article-title>
<source><![CDATA[Respir Res]]></source>
<year>2020</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>279</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[L. Ramos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Namazy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation]]></article-title>
<source><![CDATA[Immunol Allergy Clin North Am]]></source>
<year>2023</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>187-97</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Parnes]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tezepelumab in Adults with Uncontrolled Asthma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>936-46</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2023</year>
<volume>102</volume>
<numero>32</numero>
<issue>32</issue>
<page-range>e34746</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menzies-Gow]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wechsler]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Brightling]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study]]></article-title>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2023</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>425-38</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diver]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Khalfaoui]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Emson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial]]></article-title>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2021</year>
<volume>9</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1299-312</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iribarren]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rahmaoui]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2017</year>
<volume>139</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1489-1495.e5</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Panettieri]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Sjöbring]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Péterffy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials]]></article-title>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2018</year>
<volume>6</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>511-25</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menzies-Gow]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Corren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bourdin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1800-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
